A pharmacokinetic interaction study of ticagrelor and digoxin in healthy volunteers

European Journal of Clinical Pharmacology

Volumn 69, Issue 10, 2013, Pages 1801-1808

  Teng, Renli ^a   Butler, Kathleen ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Digoxin; Drug drug interactions; P glycoprotein; Pharmacokinetics; Ticagrelor

Indexed keywords

DIGOXIN; DIPHENHYDRAMINE; DRUG METABOLITE; PLACEBO; TICAGRELOR;

ADULT; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE KIDNEY FUNCTION RELATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; NORMAL HUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SKIN BRUISING; STOMATITIS; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADENOSINE; ADULT; AREA UNDER CURVE; CROSS-OVER STUDIES; DIGOXIN; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NONTHERAPEUTIC HUMAN EXPERIMENTATION; P-GLYCOPROTEIN; PURINERGIC P2Y RECEPTOR ANTAGONISTS; SUBSTRATE SPECIFICITY; YOUNG ADULT;

EID: 84884816920     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-013-1543-3     Document Type: Article

References (37)

1. Husted S, van Giezen JJ (2009) Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther 27:259-274
2. Butler K, Teng R (2010) Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. Br J Clin Pharmacol 70:65-77
3. Teng R, Butler K (2010) Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 66:487-496
4. 12 receptor antagonist, has linear pharmacokinetics and provides near complete inhibition of platelet aggregation, with reversibility of effect, in healthy subjects. Can J Clin Pharmacol 15:e426
5. Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G (2006) Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 27:1038-1047
6. Storey RF, Husted S, Harrington RA, Heptinstall S, Wilcox RG, Peters G, Wickens M, Emanuelsson H, Gurbel P, Grande P, Cannon CP (2007) Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 50:1852-1856
7. Savi P, Combalbert J, Gaich C, Rouchon MC, Maffrand JP, Berger Y, Herbert JM (1994) The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost 72:313-317
8. Teng R, Oliver S, Hayes MA, Butler K (2010) Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos 38:1514-1521
9. Zhou D, Andersson TB, Grimm SW (2011) In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction and differential kinetics. Drug Metab Dispos 39:703-710
10. von Richter O, Burk O, Fromm MF, Thon KP, Eichelbaum M, Kivisto KT (2004) Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther 75:172-183
11. Glaeser H (2011) Importance of P-glycoprotein for drug-drug interactions. Handb Exp Pharmacol 201:285-297
12. Taneva E, Bogdanova V, Shtereva N (2004) Acute coronary syndrome, comorbidity, and mortality in geriatric patients. Ann N Y Acad Sci 1019:106-110
13. Tanigawara Y, Okamura N, Hirai M, Yasuhara M, Ueda K, Kioka N, Komano T, Hori R (1992) Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J Pharmacol Exp Ther 263:840-845
14. de Lannoy I, Silverman M (1992) The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. Biochem Biophys Res Commun 189:551-557
15. Drescher S, Glaeser H, Murdter T, Hitzl M, Eichelbaum M, Fromm MF (2003) P-glycoprotein-mediated intestinal and biliary digoxin transport in humans. Clin Pharmacol Ther 73:223-231
16. Food and Drug Administration. Guidance for industry: Drug interaction studies - study design, data analysis, implications for dosing, and labeling (Feb 2012) http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf. Accessed 11 October 2012
17. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, Kroemer HK (1999) The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 104:147-153
18. Food and Drug Administration. New Drug Application #22433, Appendix 1: clinical pharmacology and biopharmaceutics review (2010) http://www.accessdata. fda.gov/drugsatfda-docs/nda/2011/022433Orig1s000ClinPharmR.pdf. Accessed 30 January 2013
19. Englund G, Hallberg P, Artursson P, Michaelsson K, Melhus H (2004) Association between the number of coadministered P-glycoprotein inhibitors and serum digoxin levels in patients on therapeutic drug monitoring. BMC Med 2:8
20. Morris SA, Hatcher HF, Reddy DK (2006) Digoxin therapy for heart failure: an update. Am Fam Physician 74:613-618
21. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM (2003) Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 289:871-878
22. Mahmud A, Bennett K, Okechukwu I, Feely J (2007) National underuse of anti-thrombotic therapy in chronic atrial fibrillation identified from digoxin prescribing. Br J Clin Pharmacol 64:706-709
23. Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen KJ, Cuisset T, Kirchhof P, Marin F (2010) Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. Thromb Haemost 103:13-28
24. NICE. Clinical guideline 36: Atrial Fibrillation - the management of atrial fibrillation. http://www.nice.org.uk/nicemedia/live/10982/30052/30052.pdf Accessed 16 May 2012
25. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH (2010) Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 31:2369-2429
26. Schmitt J, Duray G, Gersh BJ, Hohnloser SH (2009) Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J 30:1038-1045
27. Sillén H, Cook M, Davis P (2010) Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 878:2299-2306
28. Taylor A, Beerahee A, Citerone D, Davy M, Fitzpatrick K, Lopez-Gil A, Stocchi F (1999) The effect of steady-state ropinirole on plasma concentrations of digoxin in patients with Parkinson's disease. Br J Clin Pharmacol 47:219-222
29. Schwartz JI, Agrawal NG, Wehling M, Musser BJ, Gumbs CP, Michiels N, De SM, Wagner JA (2008) Evaluation of the pharmacokinetics of digoxin in healthy subjects receiving etoricoxib. Br J Clin Pharmacol 66:811-817
30. Brilique, summary of product characteristics (2010) http://www.ema. europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/001241/ WC500100494.pdf. Accessed 16 February 2012
31. TM US full prescribing information (July 2011) http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/022433s000lbl.pdf. Accessed16 February 2012
32. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL (2006) ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114:e257-e354
33. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Strömberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K, ESC Committee for Practice Guidelines (CPG) (2008) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 10:933-989
34. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G (2008) Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-based Clinical Practice Guidelines (8th edition). Chest 133:160S-198S
35. Miura T, Kojima R, Sugiura Y, Mizutani M, Takatsu F, Suzuki Y (2000) Effect of aging on the incidence of digoxin toxicity. Ann Pharmacother 34:427-432
36. Digoxin Tablets [prescribing information]. West-ward Pharmaceutical Corp. Eatontown, NJ. July 2010. http://druginserts.com/lib/rx/meds/digoxin-18/. Accessed 16 February 2012
37. Siepmann M, Kleinbloesem C, Kirch W (1995) The interaction of the calcium antagonist RO 40-5967 with digoxin. Br J Clin Pharmacol 39:491-496